Cheng Liu
Vorstandsvorsitzender bei ESTRELLA IMMUNOPHARMA, INC.
Vermögen: 281 673 $ am 31.05.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Yi Ping Li | M | 59 | 7 Jahre | |
| Warner C. Greene | M | - |
InvisiShield Technologies Ltd.
 InvisiShield Technologies Ltd. Miscellaneous Commercial ServicesCommercial Services InvisiShield Technologies Ltd. is a Caymanian biotechnology company. The company is based in George Town, Cayman Islands. The company was founded by Cheng Liu, Warner C. Greene. Cheng Liu has been the CEO since incorporation. | - |
| Janelle Wu | F | - | - | |
| Krishna Viswanadhan | - | - | 5 Jahre | |
| Pei Xu | F | 42 | - | |
| Yiu Leung Cheung | M | 64 | 4 Jahre | |
| Krishnan Viswanadhan | M | 45 | 5 Jahre | |
| Ann Li Lee | M | 63 | 4 Jahre | |
| Kin Cheong Ho | M | 56 | 4 Jahre | |
| Jiandong Xu | M | 54 |
Estrella Biopharma, Inc.
 Estrella Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Estrella Biopharma, Inc. is a preclinical stage biopharmaceutical company that develops cell therapies for patients with blood cancers and solid tumors. The company is based in Emeryville, CA. The CEO of the company is Cheng Liu. | - |
| Marsha Roberts | M | 55 | - | |
| Chau Wai-Yan | M | - |
Eureka Therapeutics, Inc.
 Eureka Therapeutics, Inc. BiotechnologyHealth Technology Eureka Therapeutics, Inc. develops therapeutic monoclonal antibodies for cancer indication and treatment. It focuses on the discovery of fully-human antibody drugs for the treatment of cancer and utilizing its antibody drug discovery and engineering technologies, and advancing therapies for targeting previously inaccessible cancer antigens. The company was founded by Cheng Liu in 2006 and is headquartered in Emeryville, CA. | - |
| Fan Wu | M | 51 | - | |
| Debra Yu | M | 59 | 1 Jahre | |
| Shaun Paul Cordoba | M | 43 | 2 Jahre | |
| Sung Won Song | M | 43 | 1 Jahre | |
| Han Zhong Li | M | 56 |
Eureka Therapeutics, Inc.
Eureka Therapeutics, Inc. BiotechnologyHealth Technology Eureka Therapeutics, Inc. develops therapeutic monoclonal antibodies for cancer indication and treatment. It focuses on the discovery of fully-human antibody drugs for the treatment of cancer and utilizing its antibody drug discovery and engineering technologies, and advancing therapies for targeting previously inaccessible cancer antigens. The company was founded by Cheng Liu in 2006 and is headquartered in Emeryville, CA. | 5 Jahre |
| Hong Xia Zheng | M | 55 | 5 Jahre | |
| Vicky Yang | F | 52 | - | |
| Raymond Joseph Hage | M | 56 | 2 Jahre | |
| Xing Gao | F | 39 | 4 Jahre | |
| Vivien Chan | M | - |
Eureka Therapeutics, Inc.
Eureka Therapeutics, Inc. BiotechnologyHealth Technology Eureka Therapeutics, Inc. develops therapeutic monoclonal antibodies for cancer indication and treatment. It focuses on the discovery of fully-human antibody drugs for the treatment of cancer and utilizing its antibody drug discovery and engineering technologies, and advancing therapies for targeting previously inaccessible cancer antigens. The company was founded by Cheng Liu in 2006 and is headquartered in Emeryville, CA. | 10 Jahre |
| Michael Cannon | M | 78 |
Eureka Therapeutics, Inc.
Eureka Therapeutics, Inc. BiotechnologyHealth Technology Eureka Therapeutics, Inc. develops therapeutic monoclonal antibodies for cancer indication and treatment. It focuses on the discovery of fully-human antibody drugs for the treatment of cancer and utilizing its antibody drug discovery and engineering technologies, and advancing therapies for targeting previously inaccessible cancer antigens. The company was founded by Cheng Liu in 2006 and is headquartered in Emeryville, CA. | - |
| Ka Man Ng | F | - | 3 Jahre | |
| Mark Gilbert | M | 63 | - | |
| Jacqueline Northcut | F | 62 |
Eureka Therapeutics, Inc.
Eureka Therapeutics, Inc. BiotechnologyHealth Technology Eureka Therapeutics, Inc. develops therapeutic monoclonal antibodies for cancer indication and treatment. It focuses on the discovery of fully-human antibody drugs for the treatment of cancer and utilizing its antibody drug discovery and engineering technologies, and advancing therapies for targeting previously inaccessible cancer antigens. The company was founded by Cheng Liu in 2006 and is headquartered in Emeryville, CA. | - |
| Marvin Samson | M | 82 |
Eureka Therapeutics, Inc.
Eureka Therapeutics, Inc. BiotechnologyHealth Technology Eureka Therapeutics, Inc. develops therapeutic monoclonal antibodies for cancer indication and treatment. It focuses on the discovery of fully-human antibody drugs for the treatment of cancer and utilizing its antibody drug discovery and engineering technologies, and advancing therapies for targeting previously inaccessible cancer antigens. The company was founded by Cheng Liu in 2006 and is headquartered in Emeryville, CA. | - |
| Bo Feng | M | 53 |
Eureka Therapeutics, Inc.
Eureka Therapeutics, Inc. BiotechnologyHealth Technology Eureka Therapeutics, Inc. develops therapeutic monoclonal antibodies for cancer indication and treatment. It focuses on the discovery of fully-human antibody drugs for the treatment of cancer and utilizing its antibody drug discovery and engineering technologies, and advancing therapies for targeting previously inaccessible cancer antigens. The company was founded by Cheng Liu in 2006 and is headquartered in Emeryville, CA. | - |
| Chih Kai Cheng | M | - |
Eureka Therapeutics, Inc.
Eureka Therapeutics, Inc. BiotechnologyHealth Technology Eureka Therapeutics, Inc. develops therapeutic monoclonal antibodies for cancer indication and treatment. It focuses on the discovery of fully-human antibody drugs for the treatment of cancer and utilizing its antibody drug discovery and engineering technologies, and advancing therapies for targeting previously inaccessible cancer antigens. The company was founded by Cheng Liu in 2006 and is headquartered in Emeryville, CA. | - |
| William S. Solari | M | - |
Eureka Therapeutics, Inc.
Eureka Therapeutics, Inc. BiotechnologyHealth Technology Eureka Therapeutics, Inc. develops therapeutic monoclonal antibodies for cancer indication and treatment. It focuses on the discovery of fully-human antibody drugs for the treatment of cancer and utilizing its antibody drug discovery and engineering technologies, and advancing therapies for targeting previously inaccessible cancer antigens. The company was founded by Cheng Liu in 2006 and is headquartered in Emeryville, CA. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Yan Ling Cao | M | 39 | 1 Jahre | |
| Chi Shing Li | M | 67 | - | |
| Hans Bishop | M | 59 | 4 Jahre | |
| Suet Wing Leung | F | 35 | - | |
| Kwok Fai Lee | M | - | - | |
| Jin Yin Wang | M | 47 | 3 Jahre | |
| Xin Fu | M | 46 | 3 Jahre | |
| Alexa Willson | F | - |
Eureka Therapeutics, Inc.
Eureka Therapeutics, Inc. BiotechnologyHealth Technology Eureka Therapeutics, Inc. develops therapeutic monoclonal antibodies for cancer indication and treatment. It focuses on the discovery of fully-human antibody drugs for the treatment of cancer and utilizing its antibody drug discovery and engineering technologies, and advancing therapies for targeting previously inaccessible cancer antigens. The company was founded by Cheng Liu in 2006 and is headquartered in Emeryville, CA. | - |
| Christopher L. Lehman | M | 63 |
Eureka Therapeutics, Inc.
Eureka Therapeutics, Inc. BiotechnologyHealth Technology Eureka Therapeutics, Inc. develops therapeutic monoclonal antibodies for cancer indication and treatment. It focuses on the discovery of fully-human antibody drugs for the treatment of cancer and utilizing its antibody drug discovery and engineering technologies, and advancing therapies for targeting previously inaccessible cancer antigens. The company was founded by Cheng Liu in 2006 and is headquartered in Emeryville, CA. | 2 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| China | 21 | 53,85% |
| Vereinigte Staaten | 17 | 43,59% |
| Cayman Islands | 1 | 2,56% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
